Cell News and Research

RSS

Envoy Therapeutics secures loan from Takeda Research Investment

Envoy Therapeutics, Inc., a newly formed drug discovery company, today announced that it has secured a loan from Takeda Research Investment (TRI) which Envoy may elect to convert to Envoy preferred stock should the company complete a second private equity financing. TRI will receive certain rights from Envoy related to a specific therapeutic field while scientists at the two companies craft a broad scientific research alliance.

11 Nov 2009

Osteotech highlights Magnifuse bone grafting products at NASS Annual Meeting

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, today announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products for different spine therapy areas at the North American Spine Society (NASS) 2009 Annual Meeting, taking place November 10th through 14th in San Francisco, California. To date MagniFuse has been used in 40 spinal surgeries in the United States

11 Nov 2009

New microplate for BioFlux live cell imaging workstations

Fluxion Biosciences introduces a new microplate for its BioFlux live cell imaging workstations, extending their shear flow limits to simulate a variety of pathological vascular conditions. With the new High Shear Plate, the BioFlux systems can be an effective tool in thrombosis and platelet studies, cardiovascular and immunological drug screening and cell/bacteria adhesion research.

From Fluxion Biosciences 11 Nov 2009

Researchers find link between two genes involved in cancer formation in humans

Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment.

11 Nov 2009

Researchers identify new mechanism to create lasting memories; findings may yield potential treatment for memory impairments

Researchers at the Swedish medical university Karolinska Institutet have discovered a mechanism that controls the brain's ability to create lasting memories. In experiments on genetically manipulated mice, they were able to switch on and off the animals' ability to form lasting memories by adding a substance to their drinking water. The findings, which are published in the scientific journal PNAS, are of potential significance to the future treatment of Alzheimer's and stroke.

11 Nov 2009

OncoVista Innovative Therapies' AdnaTest BreastCancer and EMT1/StemCell products evaluated in German hospitals

OncoVista Innovative Therapies, Inc. reported today that two of its proprietary products, the AdnaTest™ BreastCancer and AdnaTest EMT1/StemCell, were evaluated in Germany by the Departments of Gynecology and Obstetrics and Internal Medicine (Cancer Research) at University Hospital Essen, University of Duisburg-Essen and the Department of Gynecology and Obstetrics, University Hospital of Tuebingen.

11 Nov 2009

New non-invasive procedures may help in reducing localized fat safely and effectively

For many people, diet and exercise help keep them looking and feeling healthy. But even those who work hard on staying in shape might have a hard time shaking stubborn love handles or lower belly fat, which can bulge through clothing like a neon sign. While the market for getting rid of unwanted fat has grown over the years to include stomach stapling and behavioral techniques, there is still a demand for procedures that can reduce areas of localized fat safely and effectively.

11 Nov 2009

Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

Poniard Pharmaceuticals, Inc. today announced that the Company will present updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC) and final results from its Phase 1 cardiac safety trial.

11 Nov 2009

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.

11 Nov 2009

"Microsoft Health Tech Today" showcases how software innovation is improving global health

Microsoft Corp. today announced "Microsoft Health Tech Today," a fast-paced online video series designed to showcase how software innovation is improving health around the world. The show, at the intersection of health and information technology, highlights the latest industry trends and features examples of proven solutions that are improving health and changing lives for clinicians, patients and consumers worldwide.

11 Nov 2009

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.

11 Nov 2009

Academic Health Center receives 128 grants totaling nearly $35 million in federal stimulus money

Academic Health Center scientists, physicians, and research centers have attracted 128 grants totaling nearly $35 million in federal stimulus money (as of Nov. 10) since the American Recovery and Reinvestment Act was approved in February 2009. This will result in a total economic impact of more than $105 million; according to the National Institutes of Health, $1 of research funding multiplies to more than $2 of goods and services in the economy.

11 Nov 2009

NIDA supports new drug detection research

Every time a person snorts cocaine, it doesn't just go to his or her head: It also provokes a response in the immune system, creating special biomolecules that may serve as a permanent record of each exposure.

11 Nov 2009

Sprycel holds hope for treating Src dependent ovarian cancer

The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

11 Nov 2009

Researchers identify cause that leads to age-related hearing loss

Age-related hearing loss is the most common sensory disorder among the elderly. But scientists are still trying to figure out what cellular processes govern or contribute to the loss.

11 Nov 2009

HFSP grant to develop molecular probes to study "cellular GPS" system

An international group of researchers from Carnegie Mellon University, Goettingen Medical School in Germany and the University of Cambridge in the United Kingdom have received a Human Frontiers Science Program (HFSP) grant to develop molecular probes that will help researchers better understand the "cellular GPS" system that guides neurons to create a properly wired nervous system.

11 Nov 2009

Anemia-reducing medications linked to deep vein thrombosis in cancer patients

Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. The findings will be published online on Nov. 10, 2009 in the Journal of the National Cancer Institute (ahead of the Dec. 2, 2009 print edition).

11 Nov 2009

Potential new drug for lung cancer eliminates tumors in mice

A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.

11 Nov 2009

Texting linked to pain in neck and shoulders among college students

The world record for fastest text message typing is held by a 21-year old college student from Utah, but his dexterous digits could mean serious injury later on. Most adults aged 18-21 prefer texting over e-mail or phone calls, and ergonomics researchers are starting to wonder whether it's putting the younger generation at risk for some overuse injuries - once reserved for older adults who have spent years in front of a computer.

10 Nov 2009

NIH $1 million Challenge Grant to refine cell-tracking nanotube technology

The National Institutes of Health (NIH) has awarded researchers at Rice University and the Texas Heart® Institute (THI) a $1 million Challenge Grant to refine cell-tracking nanotube technology that could make magnetic resonance imaging (MRI) up to 40 times more sensitive than existing MRIs and help guide adult stem cells within the human body to repair damaged hearts.

10 Nov 2009